Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Amortizatization of Intangibles: 2020-2024

Historic Amortizatization of Intangibles for Journey Medical (DERM) over the last 5 years, with Dec 2024 value amounting to $3.4 million.

  • Journey Medical's Amortizatization of Intangibles rose 30.71% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 28.15%. This contributed to the annual value of $3.4 million for FY2024, which is 9.11% down from last year.
  • Latest data reveals that Journey Medical reported Amortizatization of Intangibles of $3.4 million as of FY2024, which was down 9.11% from $3.8 million recorded in FY2023.
  • In the past 5 years, Journey Medical's Amortizatization of Intangibles registered a high of $4.3 million during FY2022, and its lowest value of $1.4 million during FY2020.
  • Its 3-year average for Amortizatization of Intangibles is $3.8 million, with a median of $3.8 million in 2023.
  • As far as peak fluctuations go, Journey Medical's Amortizatization of Intangibles surged by 81.13% in 2021, and later decreased by 11.92% in 2023.
  • Over the past 5 years, Journey Medical's Amortizatization of Intangibles (MRY) stood at $1.4 million in 2020, then surged by 81.13% to $2.6 million in 2021, then surged by 66.29% to $4.3 million in 2022, then decreased by 11.92% to $3.8 million in 2023, then fell by 9.11% to $3.4 million in 2024.
  • Its Amortizatization of Intangibles stands at $3.4 million for FY2024, versus $3.8 million for FY2023 and $4.3 million for FY2022.